4.8 Review

Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic inflammation

期刊

FRONTIERS IN IMMUNOLOGY
卷 7, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2016.00477

关键词

tertiary lymphoid structures; chemokines; tumor necrosis factor-alpha; lymphotoxin alpha1; beta2 heterotrimer; fibroblasts

资金

  1. Arthritis Research UK [20298]
  2. Medical Research Council [MR/M009157/1, G9818340, 1483629] Funding Source: researchfish
  3. Versus Arthritis [21236, 19791] Funding Source: researchfish
  4. MRC [MR/M009157/1, G9818340] Funding Source: UKRI

向作者/读者索取更多资源

Tertiary lymphoid structures (TLS) are organized aggregates of lymphocytes, myeloid, and stromal cells that provide ectopic hubs for acquired immune responses. TLS share phenotypical and functional features with secondary lymphoid organs (SLO); however, they require persistent inflammatory signals to arise and are often observed at target sites of autoimmune disease, chronic infection, cancer, and organ transplantation. Over the past 10 years, important progress has been made in our understanding of the role of stromal fibroblasts in SLO development, organization, and function. A complex and stereotyped series of events regulate fibroblast differentiation from embryonic life in SLOs to lymphoid organ architecture observed in adults. In contrast, TLS-associated fibroblasts differentiate from postnatal, locally activated mesenchyme, predominantly in settings of inflammation and persistent antigen presentation. Therefore, there are critical differences in the cellular and molecular requirements that regulate SLO versus TLS development that ultimately impact on stromal and hematopoietic cell function. These differences may contribute to the pathogenic nature of TLS in the context of chronic inflammation and malignant transformation and offer a window of opportunity for therapeutic interventions in TLS associated pathologies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据